Ligand Pharm (LGND)

$129.63 +5.33 (4.29%)
Market Cap 2.40B
Revenue (ttm) 167.13M
Net Income (ttm) -4.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 928.68
Profit Margin -2.41%
Debt to Equity Ratio 0.00
Volume 290,700
Avg Vol 132,902
Day's Range N/A - N/A
Shares Out 19.29M
Stochastic %K 93%
Beta 0.84
Analysts Strong Sell
Price Target $142.62

Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pn...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 550 7500
Address:
555 Heritage Drive, Suite 200, Jupiter, United States
Trade4Profits007
Trade4Profits007 Jul. 11 at 10:12 PM
$PTHS $LGND owns 49% of the stock. Ligand CEO stated “We look forward to more exciting developments from Pelthos in the coming months”. - More news coming soon
1 · Reply
StocktwitsNews
StocktwitsNews Jul. 11 at 2:22 AM
Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts $PTHS $LGND https://stocktwits.com/news/equity/markets/pelthos-ligand-gain-after-launch-of-first-prescription-at-home-treatment-for-water-warts/ch8TDAvR5lI
0 · Reply
StockPortfolioManager
StockPortfolioManager Jul. 9 at 4:08 PM
🚀 3 Safe Stocks Surging Today: $FUTU, $AES & $LGND – Long-Term Winners! Looking for stocks with strong growth AND stability? Here are 3 top picks: 🔥 Futu Holdings (FUTU) – Fintech leader with +87% in a year! 💡 AES Corp (AES) – Undervalued utility stock (+17% today). 💊 Ligand Pharma (LGND) – Steady biotech play with a solid pipeline. Why invest? ✅ Strong market caps (2B-19B) ✅ Mix of growth & stability ✅ Surging today but built for long-term gains Perfect for a balanced portfolio! 💰
0 · Reply
Doozio
Doozio Jul. 9 at 12:33 PM
Gap n GOGO’s with da huckleberries thru da $$$ get in $RYTM NOW TTWO BYRN da 🐑! if $KWEB can join this 🎉 its gonna a get $LGND ary out of the tightness 🐒🍌🧠⏰♾️
0 · Reply
Estimize
Estimize Jul. 7 at 7:02 PM
Wall St is expecting 1.42 EPS for $LGND Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/lgnd?chart=historical&metric_name=eps&utm_co
0 · Reply
themacromindset
themacromindset Jul. 7 at 3:11 PM
$PTHS $LGND Pelthos Therapeutics 13D Filing Shows Ligand Pharmaceuticals Discloses 49.9% Stake As Of July 1, 2025
0 · Reply
Doozio
Doozio Jul. 4 at 5:01 PM
$LGND s are made out of the tightness in $RYTM during 🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Jul. 1 at 4:28 PM
$XBI is finding its $RYTM in $HRMY and its about TTWO get $LGND ry during 🐒🍌🧠⏰♾️
1 · Reply
Estimize
Estimize Jun. 30 at 1:00 PM
Wall St is expecting 1.42 EPS for $LGND Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/lgnd?chart=historical&metric_name=eps&utm_co
0 · Reply
WAJeff
WAJeff Jun. 26 at 11:22 PM
$LGND Lost track of this one since the $60S in 2023. Can’t own ‘em all, I guess.
0 · Reply
Latest News on LGND
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

Jul 10, 2025, 8:00 AM EDT - 6 days ago

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

Jul 2, 2025, 7:00 AM EDT - 15 days ago

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

Jul 2, 2025, 7:00 AM EDT - 15 days ago

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward

Jun 24, 2025, 2:47 PM EDT - 22 days ago

Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward

Ligand Announces 2025 Investor Day in New York City

Jun 11, 2025, 7:00 AM EDT - 5 weeks ago

Ligand Announces 2025 Investor Day in New York City

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

May 14, 2025, 7:00 AM EDT - 2 months ago

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript

May 8, 2025, 2:19 PM EDT - 2 months ago

Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript

Ligand Reports First Quarter 2025 Financial Results

May 8, 2025, 7:00 AM EDT - 2 months ago

Ligand Reports First Quarter 2025 Financial Results

Ligand to Participate in May Investor Conferences

May 1, 2025, 7:00 AM EDT - 2 months ago

Ligand to Participate in May Investor Conferences

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 24, 2025, 7:00 AM EDT - 3 months ago

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Apr 17, 2025, 6:00 AM EDT - 3 months ago

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Ligand to Participate in March Investor Conferences

Mar 3, 2025, 7:00 AM EST - 4 months ago

Ligand to Participate in March Investor Conferences

Ligand Pharmaceuticals Incorporated (LGND) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 3:06 PM EST - 4 months ago

Ligand Pharmaceuticals Incorporated (LGND) Q4 2024 Earnings Call Transcript

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 4 months ago

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

Feb 25, 2025, 7:00 AM EST - 5 months ago

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

XOMA

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Feb 13, 2025, 7:00 AM EST - 5 months ago

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 6, 2025, 7:00 AM EST - 5 months ago

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Looking Back On Ligand Pharmaceuticals

Feb 3, 2025, 2:59 PM EST - 5 months ago

Looking Back On Ligand Pharmaceuticals

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Jan 13, 2025, 6:10 PM EST - 6 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

Dec 10, 2024, 9:00 AM EST - 7 months ago

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies

Nov 24, 2024, 6:50 AM EST - 8 months ago

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies

Ligand to Present at Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 8 months ago

Ligand to Present at Stifel 2024 Healthcare Conference

Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 8:07 AM EST - 8 months ago

Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Nov 7, 2024, 7:00 AM EST - 8 months ago

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Nov 1, 2024, 8:01 AM EDT - 9 months ago

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Oct 23, 2024, 4:01 PM EDT - 9 months ago

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Sep 6, 2024, 9:20 AM EDT - 11 months ago

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

TVTX

CD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030

Aug 30, 2024, 4:04 AM EDT - 11 months ago

CD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 20, 2024, 9:00 AM EDT - 11 months ago

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

Ligand Pharmaceuticals Incorporated (LGND) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 10:58 PM EDT - 1 year ago

Ligand Pharmaceuticals Incorporated (LGND) Q2 2024 Earnings Call Transcript

Ligand Reports Second Quarter 2024 Financial Results

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Ligand Reports Second Quarter 2024 Financial Results

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Jul 29, 2024, 2:43 PM EDT - 1 year ago

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement

Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024

Jul 23, 2024, 4:01 PM EDT - 1 year ago

Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024

Ligand to Acquire APEIRON Biologics AG for $100 Million

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Ligand to Acquire APEIRON Biologics AG for $100 Million

Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults

Jun 18, 2024, 8:00 AM EDT - 1 year ago

Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults

Ligand to Participate in Upcoming Investor Conferences

May 23, 2024, 4:59 PM EDT - 1 year ago

Ligand to Participate in Upcoming Investor Conferences

Ligand Pharmaceuticals Incorporated (LGND) Q1 2024 Earnings Call Transcript

May 7, 2024, 11:03 PM EDT - 1 year ago

Ligand Pharmaceuticals Incorporated (LGND) Q1 2024 Earnings Call Transcript

Ligand Reports First Quarter 2024 Financial Results

May 7, 2024, 4:00 PM EDT - 1 year ago

Ligand Reports First Quarter 2024 Financial Results

Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement

May 7, 2024, 7:30 AM EDT - 1 year ago

Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement

AGEN

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Apr 29, 2024, 10:01 PM EDT - 1 year ago

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Ligand to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 23, 2024, 8:31 AM EDT - 1 year ago

Ligand to Report First Quarter 2024 Financial Results on May 7, 2024

Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

Apr 8, 2024, 8:15 AM EDT - 1 year ago

Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™

Apr 3, 2024, 9:00 AM EDT - 1 year ago

Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™

Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference

Mar 5, 2024, 4:01 PM EST - 1 year ago

Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference

Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 4, 2024, 8:00 AM EST - 1 year ago

Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ligand Pharmaceuticals Inc. (LGND) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 11:32 AM EST - 1 year ago

Ligand Pharmaceuticals Inc. (LGND) Q4 2023 Earnings Call Transcript

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024, 7:00 AM EST - 1 year ago

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Feb 22, 2024, 4:01 PM EST - 1 year ago

Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Trade4Profits007
Trade4Profits007 Jul. 11 at 10:12 PM
$PTHS $LGND owns 49% of the stock. Ligand CEO stated “We look forward to more exciting developments from Pelthos in the coming months”. - More news coming soon
1 · Reply
StocktwitsNews
StocktwitsNews Jul. 11 at 2:22 AM
Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts $PTHS $LGND https://stocktwits.com/news/equity/markets/pelthos-ligand-gain-after-launch-of-first-prescription-at-home-treatment-for-water-warts/ch8TDAvR5lI
0 · Reply
StockPortfolioManager
StockPortfolioManager Jul. 9 at 4:08 PM
🚀 3 Safe Stocks Surging Today: $FUTU, $AES & $LGND – Long-Term Winners! Looking for stocks with strong growth AND stability? Here are 3 top picks: 🔥 Futu Holdings (FUTU) – Fintech leader with +87% in a year! 💡 AES Corp (AES) – Undervalued utility stock (+17% today). 💊 Ligand Pharma (LGND) – Steady biotech play with a solid pipeline. Why invest? ✅ Strong market caps (2B-19B) ✅ Mix of growth & stability ✅ Surging today but built for long-term gains Perfect for a balanced portfolio! 💰
0 · Reply
Doozio
Doozio Jul. 9 at 12:33 PM
Gap n GOGO’s with da huckleberries thru da $$$ get in $RYTM NOW TTWO BYRN da 🐑! if $KWEB can join this 🎉 its gonna a get $LGND ary out of the tightness 🐒🍌🧠⏰♾️
0 · Reply
Estimize
Estimize Jul. 7 at 7:02 PM
Wall St is expecting 1.42 EPS for $LGND Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/lgnd?chart=historical&metric_name=eps&utm_co
0 · Reply
themacromindset
themacromindset Jul. 7 at 3:11 PM
$PTHS $LGND Pelthos Therapeutics 13D Filing Shows Ligand Pharmaceuticals Discloses 49.9% Stake As Of July 1, 2025
0 · Reply
Doozio
Doozio Jul. 4 at 5:01 PM
$LGND s are made out of the tightness in $RYTM during 🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Jul. 1 at 4:28 PM
$XBI is finding its $RYTM in $HRMY and its about TTWO get $LGND ry during 🐒🍌🧠⏰♾️
1 · Reply
Estimize
Estimize Jun. 30 at 1:00 PM
Wall St is expecting 1.42 EPS for $LGND Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/lgnd?chart=historical&metric_name=eps&utm_co
0 · Reply
WAJeff
WAJeff Jun. 26 at 11:22 PM
$LGND Lost track of this one since the $60S in 2023. Can’t own ‘em all, I guess.
0 · Reply
Estimize
Estimize Jun. 23 at 11:00 PM
Wall St is expecting 1.42 EPS for $LGND Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/lgnd?chart=historical&metric_name=eps&utm_co
0 · Reply
Doozio
Doozio Jun. 20 at 2:19 PM
The $LGCY of 🐒🍌🧠⏰♾️ will be $LGND ary if $XBI can ever get in $RYTM with da huckleberries in $HRMY
0 · Reply
swingingtech
swingingtech Jun. 9 at 9:03 PM
$LGND https://wallstreetwaves.com/lgnd-surpasses-key-moving-average-with-bullish-momentum/
0 · Reply
Estimize
Estimize Jun. 9 at 1:01 PM
Wall St is expecting 1.42 EPS for $LGND Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/lgnd?chart=historical&metric_name=eps&utm_co
0 · Reply
SmartInsider
SmartInsider May. 20 at 10:53 AM
Ligand Pharmaceuticals Inc - $LGND US ranked positive on May 14th, 2025 Learn more: https://www.smartinsider.com/stock-of-the-week/lgnd-us-ranked-positive-on-may-14th-2025/
0 · Reply
himsssss
himsssss May. 20 at 1:19 AM
All respective positions can confirmed on their own investor relations pages Brian Lian - Named as the director in correspondence to the $LGND deal with $SEELQ https://seelostherapeutics.com/discovering-seelos-copy-2/ Bankrupt due to their compound from $LGND https://www.fiercebiotech.com/biotech/after-als-trial-misses-mark-seelos-has-filed-bankruptcy https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-notice-of-delisting-from-nasdaq-and-transfer-of-listing-to-over-the-counter-market-302276319.html Greg Zante- CFO Previously worked as CFO for dance pharmaceutical where the books were cooked. Rebranded and then ran off with investors money. https://www.drugdeliverybusiness.com/dance-biopharm-rebrands-to-aerami-therapeutics/ Aerami therapeutics running off with investors money. https://www.bizjournals.com/triangle/news/2024/08/30/aerami-therapeutics-shuts-down-closed-drugs-pharma.html
0 · Reply
King990
King990 May. 19 at 11:11 PM
$VKTX $LGND Another fraud account, this short will get his ASS squeeze hard soon.
1 · Reply
himsssss
himsssss May. 19 at 10:53 PM
Lets talk about confirmation bias. $VKTX CEO and CFO. Both responsible for bankrupting companies and running with the money. Brian brought $LGND to both VKTX and SEELQ. Seelq is now bankrupt due to their decision to use LGND compound as their backbone and failing the trials. Greg Zante led dance pharmaceutical which rebranded to aerami therapeutics. They ran away without a word after a $20M investment. Let's also not forget VK2735 is also just wegovy with a twist.
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures May. 14 at 2:10 AM
$LGND CEO purchased 9,510 shares at $105.20 for a total of $1,000,456. Davis Todd C now owns 161,234 shares. https://ceo-buys.com
0 · Reply
Estimize
Estimize May. 13 at 10:03 AM
Wall St is expecting 1.40 EPS for $LGND Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/lgnd?chart=historical&metric_name=eps&utm_co
0 · Reply
ZacksSCR
ZacksSCR May. 12 at 4:17 PM
$LGND: 1Q:25 Results https://buff.ly/9AE4A7J
0 · Reply